Axon Enterprise, Inc. AXON
425.74 USD +9.17 (+2.20%)
Nov 4, 2026, 1:20 PM EST
414.05 Day range 428.50
345.94 52-week range 706.13
- YTD
- -25.04%
- 1 year
- -39.71%
Analyst view
Consensus: buy
Buy
Price target (mean) 680.37 +59.8% upside
Now 425.74
- Target (low)
- 440.00
- Target (mean)
- 680.37
- Target (high)
- 830.00
Ratings (0m) 21 18 buy · 3 hold · 0 sell
- Strong buy8
- Buy10
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 21
- 1 month ago 21
- 2 months ago 21
- 3 months ago 21
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 1.89 | 1.22 – 2.46 | 1.17 | +61.6% | 934.33M | +31.5% | 18 |
| Next quarter | 2.29 | 1.47 – 2.84 | 2.15 | +6.7% | 1.07B | +34.0% | 18 |
| Current year | 7.64 | 6.19 – 8.80 | 6.85 | +11.5% | 3.71B | +33.4% | 20 |
| Next year | 10.51 | 7.72 – 12.05 | 7.64 | +37.6% | 4.80B | +29.5% | 20 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 26, 2026 | TD Cowen | Maintained | Buy | Buy |
| Oct 20, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Sep 3, 2026 | Argus Research | Maintained | Buy | Buy |
| Aug 6, 2026 | UBS | Maintained | Neutral | Neutral |
| Aug 6, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 6, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 6, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 13, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Jul 6, 2026 | Needham | Maintained | Buy | Buy |
| Jun 25, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| May 8, 2026 | Barclays | Maintained | Overweight | Overweight |
| May 7, 2026 | UBS | Maintained | Neutral | Neutral |
| May 7, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| May 7, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| May 7, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Apr 16, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Apr 13, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Apr 8, 2026 | TD Cowen | Maintained | Buy | Buy |
| Apr 8, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Feb 25, 2026 | UBS | Maintained | Neutral | Neutral |
| Feb 25, 2026 | Barclays | Maintained | Overweight | Overweight |
| Feb 25, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Feb 25, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Feb 25, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Feb 20, 2026 | Needham | Maintained | Buy | Buy |
| Dec 17, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Nov 17, 2025 | RBC Capital | Initiated | — | Outperform |
| Nov 6, 2025 | Barclays | Maintained | Overweight | Overweight |
| Nov 5, 2025 | UBS | Maintained | Neutral | Neutral |
| Nov 5, 2025 | Goldman Sachs | Maintained | Buy | Buy |
